Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532450 | 0.85 | LMNA (0.48) | LMNA | |
| SCHEMBL918799 | 0.77 | LMNA (0.48) | LMNA | |
| SCHEMBL882914 | 0.72 | LMNA (0.44) | LMNA | |
| Trifluoroacetic Acid SCHEMBL6515639 | 0.72 | LMNA (0.53) | LMNAOR51E2 | |
| SCHEMBL7277164 | 0.72 | LMNA (0.42) | LMNA | |
| Trifluoroacetic Acid SCHEMBL29117404 | 0.72 | LMNA (0.41) | LMNAOR51E2 | |
| Trifluoroacetic Acid SCHEMBL13730794 | 0.71 | OR51E2 (0.70) | OR51E2 | |
| SCHEMBL4671980 | 0.71 | LMNA (0.36) | LMNAOR51E2 | |
| Trifluoroacetic Acid SCHEMBL30364185 | 0.69 | CYP1A2 (0.39) | LMNA | |
| SCHEMBL15360401 | 0.69 | OR51E2 (0.33) | LMNAOR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575955-B1 | PYRROLOBENZODIAZEPINES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7704924-B2 | Library of compounds comprising pyrrolobenzodiazepine moieties | SPIROGEN LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7407951-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| EP-1107969-B1 | COLLECTIONS OF COMPOUNDS | SPIROGEN LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-7265105-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| US-20060148788-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20060128693-A1 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1413582-B1 | Dimeric pyrrolobenzodiazepines | SPIROGEN LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| EP-1107970-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| EP-1107969-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012506-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012509-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012507-A2 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| EP-0344234-A1 | ANTIBIOTIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1989-12-06 | — | — | EP | disclosed |
| EP-0309161-A2 | Antibiotic compounds | BEECHAM GROUP PLC (GB) | 1989-03-29 | — | — | EP | disclosed |
| WO-1989002441-A1 | ANTIBIOTIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1989-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148788-A1 | Pyrrolobenzodiazepines | HCRTR2, MCHR2, CHRM5 | LMNA 2882/4885OR51E2 1538/4885 |
| US-20060128693-A1 | Pyrrolobenzodiazepines | CYP2C19, CYP3A7, CYP2E1 | LMNA 2314/4885OR51E2 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.